[
    [
        {
            "time": "2019-08-15",
            "original_text": "长春高新营销费用增两成，研发仅增3.79%",
            "features": {
                "keywords": [
                    "营销费用",
                    "研发",
                    "增长"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "长春高新营销费用增两成，研发仅增3.79%",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-15",
            "original_text": "受疫苗业务拖累，长春高新第二季度营收同比下降5.89%，盈利能力下降",
            "features": {
                "keywords": [
                    "疫苗业务",
                    "拖累",
                    "营收下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "受疫苗业务拖累，长春高新第二季度营收同比下降5.89%，盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-15",
            "original_text": "长春高新（000661）：业绩基本符合预期，金赛药业延续高增长态势【中报点评|西南医药朱国广陈铁林团队】",
            "features": {
                "keywords": [
                    "金赛药业",
                    "高增长",
                    "中报点评"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "长春高新（000661）：业绩基本符合预期，金赛药业延续高增长态势【中报点评|西南医药朱国广陈铁林团队】",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-15",
            "original_text": "长春高新（000661）2019年中报点评：疫苗行业冲击，金赛气势如虹",
            "features": {
                "keywords": [
                    "疫苗行业冲击",
                    "金赛",
                    "高增长"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新（000661）2019年中报点评：疫苗行业冲击，金赛气势如虹",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-15",
            "original_text": "长春高新2019年中报点评:生长激素高增长符合预期,疫苗业务下半年有望大幅好转",
            "features": {
                "keywords": [
                    "生长激素",
                    "高增长",
                    "疫苗业务",
                    "下半年好转"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春高新2019年中报点评:生长激素高增长符合预期,疫苗业务下半年有望大幅好转",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-15",
            "original_text": "长春高新:半年报增长稳健,第二季度增速有所放缓",
            "features": {
                "keywords": [
                    "半年报",
                    "增长稳健",
                    "第二季度增速放缓"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "长春高新:半年报增长稳健,第二季度增速有所放缓",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-15",
            "original_text": "医药生物行业跨市场周报:关注中报业绩与政策边际改善,紧握优质公司",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报业绩",
                    "政策边际改善",
                    "优质公司"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报:关注中报业绩与政策边际改善,紧握优质公司",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]